Cost effectiveness of prostacyclins in pulmonary arterial hypertension

Applied Health Economics and Health Policy

Volumn 10, Issue 3, 2012, Pages 175-188

  Roman, Antonio ^a   Barberà, Joan A ^b   Escribano, Pilar ^c   Sala, Maria L ^d   Febrer, Laia ^e   Oyagüez, Itziar ^f   Sabater, Eliazar ^f   Casado, Miguel Á ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Bayer HealthCare   (Spain)

^f Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Cost effectiveness; Cost utility; Epoprostenol; Iloprost; Pulmonary hypertension; Treprostinil

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH STATUS; HUMAN; LIFE YEAR GAINED; MULTIPLE CYCLE TREATMENT; PATIENT CODING; PULMONARY HYPERTENSION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SPAIN; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MARKOV CHAINS; MODELS, ECONOMIC; PROSTAGLANDINS I; QUALITY-ADJUSTED LIFE YEARS; SPAIN; VASODILATOR AGENTS;

EID: 84860005220     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11630780-000000000-00000     Document Type: Article

References (40)

1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (9): 1023-30
2. Tueller C, Stricker H, Soccal P, et al. Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly 2008; 138 (25-26): 379-84 (Pubitemid 351969707)
3. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30 (1): 104-9 (Pubitemid 47074013)
4. Humbert M, Khaltaev N, Bousquet J, et al. Pulmonary hypertension: from an orphan disease to a public health problem. Chest 2007; 132 (2): 365-7 (Pubitemid 47282361)
5. Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol 2006; 61 (3): 243-5 (Pubitemid 43382622)
6. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131 (6): 1917-28 (Pubitemid 46981654)
7. Sanchez-Romaán J,García Hernaández FJ, Castillo Palma MJ, et al.Diagnoástico y tratamiento de la hipertensioán pulmonar. Rev Clin Esp 2008; 208 (3): 142-55
8. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31 (4): 891-901
9. DAlonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991; 115: 343-9
10. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (2): 156-63
11. Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010; 104 (6): 902-10
12. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403
13. Barberà JA, Escribano P, Morales P, et al. Standards of care in pulmonary hypertension [in Spanish]. Consensus Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC). Arch Bronconeumol 2008; 44 (2): 87-99
14. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 56S-61S (Pubitemid 38759718)
15. Highland KB, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003; 124 (6): 2087-92 (Pubitemid 38010573)
16. Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics 2006; 24 (9): 903-15 (Pubitemid 44338300)
17. Vida VL, Gaitan G, Quezada E, et al. Low-dose oral sildenafil for patients with pulmonary hypertension: a costeffective solution in countries with limited resources. Cardiol Young 2007; 17 (1): 72-7 (Pubitemid 46322013)
18. Garin MC, Clark L, Chummey ECG, et al. Cost-utility treatment for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 2009; 29: 635-46
19. Stevenson MD, Macdonald FC, Langley J, et al. The costeffectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Value Health 2009; 12 (8): 1100-5
20. Chen YF, Jowett S, Barton P, et al. Clinical and costeffectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009; 13 (49): 1-320
21. Einarson TR, Granton JT, Vicente C, et al. Costeffectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 2005; 12 (8): 419-25 (Pubitemid 43109393)
22. Narine L, Hague LK, Walker JH, et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin 2005; 21 (12): 2007-16 (Pubitemid 41803112)
23. Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based costminimization analysis. Appl Health Econ Health Policy 2009; 7: 43-59
24. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 40S-47S (Pubitemid 38759716)
25. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprostfor severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322-9 (Pubitemid 34815354)
26. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302
27. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary artery hypertension. Am J Respir Crit Care Med 2002; 165: 800-4 (Pubitemid 34229650)
28. Loápez Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guiáa para la evaluacioán econoámica aplicada a las tecnologiáas sanitarias. Gac Sanit 2010; 24: 154-70
29. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 48S-55S (Pubitemid 38759717)
30. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153 (6): 1037-47 (Pubitemid 46809838)
31. Goámez Saánchez MA, Escribano Subiáas P. Protocolos de actuacioán en hipertensioán arterial pulmonar. Unidad de Insuficiencia Cardiáaca e Hipertensioán Pulmonar. Hospital Universitario Doce de Octubre. Madrid: Editores Meádicos, s.A. EDIMSA, 2008
32. Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of Life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007; 26: 181-7 (Pubitemid 46136035)
33. Oblikue Consulting. Base de datos sanitarios e-salud [online]. Available from URL: http://www.oblikue.com/ bddcostes/ [Accessed 2010 Jul 27]
34. Consejo General de Colegios de Farmaceáuticos. Cataálogo de Especialidades Farmaceáuticas. Consejo Plus 2009. Madrid: Consejo General de Colegios de Farmaceáuticos 2007. Available from URL: http://www.portalfarma.com [Accessed 2010 Jul 27]
35. Briggs A, Claxton K, Sculpher M. Choosing distributions for parameters. In: Decision modelling for health economic evaluation. New York: Oxford University Press, 2007: 84-93
36. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500 (Pubitemid 30398806)
37. Sacristaán JA, Oliva J, Del Llano J, et al. Queáes una tecnologi áa sanitaria eficiente en España? Gac San 2002; 16: 334-43
38. Goeree R, Burke N, OReilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results form one geographic area for another. Curr Med Res Opin 2007; 23: 671-82 (Pubitemid 46631471)
39. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-63
40. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-94